IC

Ikarian Capital Portfolio holdings

AUM $302M
1-Year Return 65.21%
This Quarter Return
-4.43%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
AUM
$307M
AUM Growth
-$43.3M
Cap. Flow
+$19.6M
Cap. Flow %
6.4%
Top 10 Hldgs %
39.15%
Holding
181
New
26
Increased
23
Reduced
31
Closed
32

Sector Composition

1 Healthcare 95.44%
2 Consumer Staples 0%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Shares
Change %
Capital Flow
EVAX
101
Evaxion A/S American Depositary Share
EVAX
$18.4M
$148K 0.02%
+80,000
New +$148K
RZLT icon
102
Rezolute
RZLT
$696M
$145K 0.02%
50,058
-807,172
-94% -$2.34M
LYRA icon
103
Lyra Therapeutics
LYRA
$11.3M
$134K 0.02%
21,163
TOVX icon
104
Theriva Biologics
TOVX
$3.88M
$132K 0.02%
+120,031
New +$132K
LRMR icon
105
Larimar Therapeutics
LRMR
$337M
$126K 0.02%
58,526
JSPR icon
106
Jasper Therapeutics
JSPR
$44.2M
$108K 0.01%
25,107
-30,000
-54% -$129K
KPTI icon
107
Karyopharm Therapeutics
KPTI
$57.2M
$102K 0.01%
27,257
-3
-0% -$11
MGNX icon
108
MacroGenics
MGNX
$126M
$102K 0.01%
80,071
TKNO icon
109
Alpha Teknova
TKNO
$233M
$72.7K 0.01%
+14,008
New +$72.7K
TRAW icon
110
Traws Pharma
TRAW
$12.6M
$65.5K 0.01%
28,493
-70,000
-71% -$161K
HOOK
111
DELISTED
HOOKIPA Pharma
HOOK
$57.2K 0.01%
52,996
SGMT icon
112
Sagimet Biosciences
SGMT
$231M
$39.1K ﹤0.01%
11,984
AMIX
113
Autonomix Medical
AMIX
$6.32M
$35K ﹤0.01%
20,000
SYBX icon
114
Synlogic
SYBX
$17.1M
$25.3K ﹤0.01%
20,422
NMRA icon
115
Neumora Therapeutics
NMRA
$272M
$15.5K ﹤0.01%
+15,457
New +$15.5K
RLMD icon
116
Relmada Therapeutics
RLMD
$54.8M
$10.9K ﹤0.01%
40,270
MIST icon
117
Milestone Pharmaceuticals
MIST
$153M
-466,030
Closed -$1.1M
ACLX icon
118
Arcellx
ACLX
$4.03B
0
AEON icon
119
AEON Biopharma
AEON
$8.89M
-3,577
Closed -$139K
ALGS icon
120
Aligos Therapeutics
ALGS
$78.8M
-64,300
Closed -$2.56M
ALT icon
121
Altimmune
ALT
$334M
0
AMGN icon
122
Amgen
AMGN
$153B
0
AMLX icon
123
Amylyx Pharmaceuticals
AMLX
$910M
-201,187
Closed -$760K
ANAB icon
124
AnaptysBio
ANAB
$613M
0
APGE icon
125
Apogee Therapeutics
APGE
$2.26B
0